EuroPCR 2023: Late-Breaking Science Video Collection
Published: 18 May 2023
-
Views:
1838
-
Likes:
7
-
Views:
1838
-
Likes:
7
-
Up Next -
4m 59sPart 1 | Session 6 TVT Registry Analysis: TAVR in Patients with Cardiogenic Shock -
2m 35sPart 1 | Session 7 FAME III Three-Year Follow-Up
-
29m 21sPart 2 | Session 1 View from the Thoraxcenter: EuroPCR 23 Late-breaking Science Preview -
30m 41sPart 2 | Session 2 View from the Thoraxcenter: What's Hot at EuroPCR 23?
-
1m 5sPart 4 | Session 1 Dr Lim: Patient Care and Finding Your Passion -
1m 51s -
1m 45sPart 4 | Session 3 Dr Sorajja: Why He Chose Cardiovascular Medicine
-
5m 41sPart 1 | Session 1 EBC TWO Five Year Follow-Up: Two-Stent Vs One for Large Bifurcation Lesions Sandeep Arunothayaraj
-
6m 12sPart 1 | Session 2 BASILICA Vs Chimney-Stenting for TAVR-Related Coronary Obstruction Antonio Mangieri
-
3m 15sPart 1 | Session 3 DRAGONFLY-DMR: Safety and Effectiveness of Dragonfly TMVR System for Mitral Regurgitation D Scott Lim
-
3m 30sPart 1 | Session 4 TRILUMINATE Pivotal: TEER for Tricuspid Regurgitation Paul Sorajja
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023.
More from this programme
Part 1
Expert Interviews
Short, concise overviews of the key data revealed at EuroPCR 2023, focussing on the results and impact on future research.
Part 2
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023.
Part 3
Highlights Reviews
Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.
Part 4
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
EuroPCR 23 - Join us as we discover the latest findings from a three-year follow-up of the EBC MAIN Trial, as we interview Principal Investigator Dr David Hildick-Smith (Brighton and Sussex University Hospitals, UK) onsite at EuroPCR 23.
The EBC Main Trial aimed to investigate the outcomes of single-stent versus dual-stent bifurcation treatment of distal left main coronary artery lesions. This study followed this patient population of 450 for three years.
Questions:
- What is the importance of the EBC Main study?
- What was the study design and patient population?
- How were operator experience and expertise accounted for in the trial?
- What are the main findings?
- What are the take home messages?
- What are the next steps?
Recorded on-site at EuroPCR 2023 in Paris.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent and Oliver Miles
Faculty Biographies
David Hildick-Smith
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.
Comments